首页> 外文期刊>Drug metabolism letters >Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa- implications for herb- drug interactions
【24h】

Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa- implications for herb- drug interactions

机译:非洲艾滋病毒/艾滋病患者使用的常用草药对主要药物代谢CYP的抑制作用-对草药-药物相互作用的影响

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study was to evaluate the potential risk of common herbal medicines used by HIV-infected patients in Africa for herb-drug interactions (HDI). High throughput screening assays consisting of recombinant Cytochrome P450 enzymes (CYPs) and fluorescent probes, and parallel artificial membrane permeability assays (PAMPA) were used. The potential of herbal medicines to cause HDI was ranked according to FDA guidelines for reversible inhibition and categorization of time dependent inhibition was based on the normalized ratio. CYPs 1A2 and 3A4 were most inhibited by the herbal extracts. H. hemerocallidea (IC50 = 0.63 μg/mL and 58 μg/mL) and E. purpurea (IC50 = 20 μg/mL and 12 μg/mL) were the potent inhibitors of CYPs 1A2 and 3A4 respectively. L. frutescens and H. hemerocallidea showed clear time dependent inhibition on CYP3A4. Furthermore, the inhibitory effect of both H. hemerocallidea and L. frutescens before and after PAMPA were identical. The results indicate potential HDI of H. hemerocallidea, L. frutescens and E. purpurea with substrates of the affected enzymes if maximum in vivo concentration is achieved.
机译:这项研究的目的是评估非洲受HIV感染的患者使用的常见草药对草药-药物相互作用(HDI)的潜在风险。使用了由重组细胞色素P450酶(CYP)和荧光探针组成的高通量筛选测定,以及平行人工膜通透性测定(PAMPA)。根据FDA可逆性抑制指南对草药引起HDI的潜力进行了排名,时间依赖性抑制的分类基于归一化比率。 CYP 1A2和3A4受到草药提取物的最大抑制作用。 H.hemerocallidea(IC50 = 0.63μg/ mL和58μg/ mL)和E. purpurea(IC50 = 20μg/ mL和12μg/ mL)分别是CYP 1A2和3A4的有效抑制剂。 L. frutescens和H. hemerocallidea对CYP3A4表现出明显的时间依赖性抑制作用。此外,在PAMPA之前和之后,H.hemerocallidea和F. frutescens的抑制作用是相同的。结果表明,如果达到最大体内浓度,则可能会导致半球状嗜血杆菌,弗氏乳杆菌和紫癜的潜在HDI带有受影响酶的底物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号